Organogenesis Inc. is a development-stage medical device company that designs and develops regenerative hydrogel implants for tissue repair. The company's lead product, GelrinC, is a biocompatible hydrogel-based injectable intended to treat tissue defects caused by trauma, surgery, or disease, and has received regulatory approval in Europe while pursuing FDA clearance in the United States through clinical trials. The company generates no revenue today but plans to commercialize GelrinC through direct sales, marketing, and distribution to surgeons and healthcare systems, with revenue contingent on FDA approval, manufacturing scale-up, market acceptance, adequate reimbursement, and successful surgeon adoption.